{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:03:16Z","timestamp":1790161396716,"version":"4.1.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10380-9","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:55:15Z","timestamp":1790153715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications"],"prefix":"10.1007","volume":"45","author":[{"given":"Yiting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"5","key":"10380_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41580-020-0218-z","volume":"21","author":"M Tarsounas","year":"2020","unstructured":"Tarsounas, M., & Sung, P. (2020). The antitumorigenic roles of BRCA1\u2013BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology, 21(5), 284\u2013299.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"12","key":"10380_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.molmed.2017.10.007","volume":"23","author":"GM O\u2019Kane","year":"2017","unstructured":"O\u2019Kane, G. M., Connor, A. A., & Gallinger, S. (2017). Characterization, detection, and treatment approaches for homologous recombination deficiency in cancer. Trends in Molecular Medicine, 23(12), 1121\u20131137.","journal-title":"Trends in Molecular Medicine"},{"issue":"1","key":"10380_CR3","first-page":"31","volume":"61","author":"TA Yap","year":"2011","unstructured":"Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011). Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA: A Cancer Journal for Clinicians, 61(1), 31\u201349.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"10380_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41556-019-0282-9","volume":"21","author":"K Nakamura","year":"2019","unstructured":"Nakamura, K., Saredi, G., Becker, J. R., Foster, B. M., Nguyen, N. V., Beyer, T. E., et al. (2019). H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. Nature Cell Biology, 21(3), 311\u20138.","journal-title":"Nature Cell Biology"},{"issue":"4","key":"10380_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41588-023-01298-x","volume":"55","author":"K Nee","year":"2023","unstructured":"Nee, K., Ma, D., Nguyen, Q. H., Pein, M., Pervolarakis, N., Insua-Rodr\u00edguez, J., et al. (2023). Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis. Nature Genetics, 55(4), 595\u2013606.","journal-title":"Nature Genetics"},{"key":"10380_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl9283","author":"A Degasperi","year":"2022","unstructured":"Degasperi, A., Zou, X., Amarante, T. D., Martinez-Martinez, A., Koh, G. C. C., Dias, J. M. L., et al. (2022). Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science, 376(6591), science.abl9283.","journal-title":"Science"},{"issue":"8","key":"10380_CR7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta, M., George, A., Kaye, S. B., & Banerjee, S. (2016). BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Annals of Oncology, 27(8), 1449\u20131455.","journal-title":"Annals of Oncology"},{"issue":"33","key":"10380_CR8","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1200\/JCO.23.00561","volume":"41","author":"D Mandelker","year":"2023","unstructured":"Mandelker, D., Marra, A., Zheng-Lin, B., Selenica, P., Blanco-Heredia, J., Zhu, Y., et al. (2023). Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. Journal of Clinical Oncology, 41(33), 5151\u201362.","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10380_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","volume":"35","author":"E Harvey-Jones","year":"2024","unstructured":"Harvey-Jones, E., Raghunandan, M., Robbez-Masson, L., Magraner-Pardo, L., Alaguthurai, T., Yablonovitch, A., et al. (2024). Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Annals of Oncology, 35(4), 364\u2013380.","journal-title":"Annals of Oncology"},{"issue":"5","key":"10380_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100276","volume":"2","author":"T Qing","year":"2021","unstructured":"Qing, T., Jun, T., Lindblad, K. E., Lujambio, A., Marczyk, M., Pusztai, L., et al. (2021). Diverse immune response of DNA damage repair-deficient tumors. Cell Reports Medicine, 2(5), Article 100276.","journal-title":"Cell Reports Medicine"},{"issue":"7970","key":"10380_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","volume":"619","author":"AVR Kornepati","year":"2023","unstructured":"Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023). The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature, 619(7970), 475\u201386.","journal-title":"Nature"},{"key":"10380_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309755","author":"J Qiu","year":"2024","unstructured":"Qiu, J., Ren, T., Liu, Q., Jiang, Q., Wu, T., Cheng, L. C., et al. (2024). Dissecting the distinct tumor microenvironments of HRD and HRP ovarian cancer: Implications for targeted therapies to overcome PARPi resistance in HRD tumors and refractoriness in HRP tumors. Advanced Science, 11(38), e2309755.","journal-title":"Advanced Science"},{"issue":"1","key":"10380_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41467-022-28389-3","volume":"13","author":"IM Launonen","year":"2022","unstructured":"Launonen, I. M., Lyytik\u00e4inen, N., Casado, J., Anttila, E. A., Szab\u00f3, A., Haltia, U. M., et al. (2022). Single-cell tumor-immune microenvironment of BRCA1\/2 mutated high-grade serous ovarian cancer. Nature Communications, 13(1), 835.","journal-title":"Nature Communications"},{"issue":"12","key":"10380_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","volume":"54","author":"DW Garsed","year":"2022","unstructured":"Garsed, D. W., Pandey, A., Fereday, S., Kennedy, C. J., Takahashi, K., Alsop, K., et al. (2022). The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nature Genetics, 54(12), 1853\u20131864.","journal-title":"Nature Genetics"},{"issue":"5","key":"10380_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41588-022-01041-y","volume":"54","author":"E Danenberg","year":"2022","unstructured":"Danenberg, E., Bardwell, H., Zanotelli, V. R. T., Provenzano, E., Chin, S. F., Rueda, O. M., et al. (2022). Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nature Genetics, 54(5), 660\u2013669.","journal-title":"Nature Genetics"},{"key":"10380_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101115","volume":"76","author":"WF Hong","year":"2024","unstructured":"Hong, W. F., Zhang, F., Wang, N., Bi, J. M., Zhang, D. W., Wei, L. S., et al. (2024). Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma. Drug Resist Updat., 76, Article 101115.","journal-title":"Drug Resist Updat."},{"key":"10380_CR17","doi-asserted-by":"crossref","unstructured":"Zwimpfer, T. A., Fereday, S., Pandey, A., Ariyaratne, D., Jayawardana, M. W., Twomey, L., et al. (2026). Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.\u00a0Nature Communications, 17(1), 4789.","DOI":"10.1038\/s41467-026-71134-3"},{"issue":"7689","key":"10380_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature25432","volume":"553","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum, S. F., Ngo, B., Laughney, A. M., Cavallo, J. A., Murphy, C. J., Ly, P., et al. (2018). Chromosomal instability drives metastasis through a cytosolic DNA response. Nature, 553(7689), 467\u2013472.","journal-title":"Nature"},{"issue":"7","key":"10380_CR19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41590-024-01872-3","volume":"25","author":"KRB Lanng","year":"2024","unstructured":"Lanng, K. R. B., Lauridsen, E. L., & Jakobsen, M. R. (2024). The balance of STING signaling orchestrates immunity in cancer. Nature Immunology, 25(7), 1144\u20131157.","journal-title":"Nature Immunology"},{"issue":"6710","key":"10380_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.ado3867","volume":"385","author":"R Pavani","year":"2024","unstructured":"Pavani, R., Tripathi, V., Vrtis, K. B., Zong, D., Chari, R., Callen, E., et al. (2024). Structure and repair of replication-coupled DNA breaks. Science, 385(6710), Article eado3867.","journal-title":"Science"},{"issue":"5","key":"10380_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., et al. (2023). Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cellular & Molecular Immunology, 20(5), 432\u2013447.","journal-title":"Cellular & Molecular Immunology"},{"issue":"9","key":"10380_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","volume":"20","author":"J Rehwinkel","year":"2020","unstructured":"Rehwinkel, J., & Gack, M. U. (2020). RIG-I-like receptors: Their regulation and roles in RNA sensing. Nature Reviews Immunology, 20(9), 537\u2013551.","journal-title":"Nature Reviews Immunology"},{"issue":"7","key":"10380_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015). Type I interferons in anticancer immunity. Nature Reviews Immunology, 15(7), 405\u2013414.","journal-title":"Nature Reviews Immunology"},{"issue":"7776","key":"10380_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria, O., Cornen, S., Da\u00ebron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019). Harnessing innate immunity in cancer therapy. Nature, 574(7776), 45\u201356.","journal-title":"Nature"},{"issue":"9","key":"10380_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang, K., Halima, A., & Chan, T. A. (2023). Antigen presentation in cancer - Mechanisms and clinical implications for immunotherapy. Nature Reviews Clinical Oncology, 20(9), 604\u2013623.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"5","key":"10380_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021). Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion. Nature Reviews Cancer, 21(5), 298\u2013312.","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"10380_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2021.01.011","volume":"54","author":"RW Sayaman","year":"2021","unstructured":"Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., et al. (2021). Germline genetic contribution to the immune landscape of cancer. Immunity, 54(2), 367\u201386.e8.","journal-title":"Immunity"},{"key":"10380_CR28","doi-asserted-by":"crossref","unstructured":"Park W, Umeda S, Hilmi M, O\u2019Connor C, Sharma R, Tezcan N, et al. (2026). POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer. bioRxiv, 2026.03.15.711961.","DOI":"10.64898\/2026.03.15.711961"},{"key":"10380_CR29","doi-asserted-by":"crossref","unstructured":"Trigos, A. S., Pasam, A., Banks, P., Wallace, R., Guo, C., Keam, S., et al. (2022). Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. Journal for ImmunoTherapy of Cancer, 10(6), e003744.","DOI":"10.1136\/jitc-2021-003744"},{"issue":"16","key":"10380_CR30","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1158\/1078-0432.CCR-22-0368","volume":"28","author":"RL Hollis","year":"2022","unstructured":"Hollis, R. L., Meynert, A. M., Michie, C. O., Rye, T., Churchman, M., Hallas-Potts, A., et al. (2022). Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification. Clinical Cancer Research, 28(16), 3546\u20133556.","journal-title":"Clinical Cancer Research"},{"key":"10380_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1407837","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang, Z., Li, A., Lu, Y., Han, M., Ruan, M., Wang, C., et al. (2024). Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer. Frontiers in Immunology, 15, Article 1407837.","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10380_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jnci\/djab169","volume":"114","author":"R Moretto","year":"2022","unstructured":"Moretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., et al. (2022). Homologous recombination deficiency alterations in colorectal cancer: Clinical, molecular, and prognostic implications. Journal of the National Cancer Institute, 114(2), 271\u2013279.","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10380_CR33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","volume":"1","author":"RM Samstein","year":"2021","unstructured":"Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K. W., Makarov, V., et al. (2021). Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer, 1(12), 1188\u20131203.","journal-title":"Nature Cancer"},{"issue":"3","key":"10380_CR34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.trecan.2021.12.003","volume":"8","author":"M van Vugt","year":"2022","unstructured":"van Vugt, M., & Parkes, E. E. (2022). When breaks get hot: Inflammatory signaling in BRCA1\/2-mutant cancers. Trends Cancer., 8(3), 174\u2013189.","journal-title":"Trends Cancer."},{"key":"10380_CR35","doi-asserted-by":"crossref","unstructured":"Wu, B., Qi, L., Chiang, H. C., Pan, H., Zhang, X., Greenbaum, A., et al. (2023). BRCA1 deficiency in mature CD8(+) T lymphocytes impairs antitumor immunity. Journal for ImmunoTherapy of Cancer, 11(2), e005852.","DOI":"10.1136\/jitc-2022-005852"},{"key":"10380_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103350","volume":"76","author":"X Xie","year":"2024","unstructured":"Xie, X., Chen, C., Wang, C., Guo, Y., Sun, B., Tian, J., et al. (2024). Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors. Redox Biology, 76, Article 103350.","journal-title":"Redox Biology"},{"issue":"1","key":"10380_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/76950","volume":"1","author":"TW Mak","year":"2000","unstructured":"Mak, T. W., Hakem, A., McPherson, J. P., Shehabeldin, A., Zablocki, E., Migon, E., et al. (2000). Brca1 required for T cell lineage development but not TCR loci rearrangement. Nature Immunology, 1(1), 77\u201382.","journal-title":"Nature Immunology"},{"issue":"3","key":"10380_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41577-021-00563-6","volume":"22","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Shan, Q., & Xue, H. H. (2022). TCF1 in T cell immunity: A broadened frontier. Nature Reviews Immunology, 22(3), 147\u2013157.","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10380_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12125-5","volume":"10","author":"L Ding","year":"2019","unstructured":"Ding, L., Su, Y., Fassl, A., Hinohara, K., Qiu, X., Harper, N. W., et al. (2019). Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nature Communications, 10(1), Article 4182.","journal-title":"Nature Communications"},{"issue":"3","key":"10380_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.21147\/j.issn.1000-9604.2024.03.05","volume":"36","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Ma, Y., He, L., Du, J., Li, X., Jiao, P., et al. (2024). Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis. Chinese Journal of Cancer Research, 36(3), 282\u2013297.","journal-title":"Chinese Journal of Cancer Research"},{"issue":"14","key":"10380_CR41","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-18-0468","volume":"25","author":"AA Kraya","year":"2019","unstructured":"Kraya, A. A., Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., Pluta, J., Rech, A. J., et al. (2019). Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer. Clinical Cancer Research, 25(14), 4363\u20134374.","journal-title":"Clinical Cancer Research"},{"key":"10380_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.106836","volume":"158","author":"K Kang","year":"2023","unstructured":"Kang, K., Wu, Y., Han, C., Wang, L., Wang, Z., & Zhao, A. (2023). Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response. Computers in Biology and Medicine, 158, Article 106836.","journal-title":"Computers in Biology and Medicine"},{"issue":"3","key":"10380_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41588-023-01320-2","volume":"55","author":"NL Burdett","year":"2023","unstructured":"Burdett, N. L., Willis, M. O., Alsop, K., Hunt, A. L., Pandey, A., Hamilton, P. T., et al. (2023). Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nature Genetics, 55(3), 437\u2013450.","journal-title":"Nature Genetics"},{"issue":"2","key":"10380_CR44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jtho.2023.09.276","volume":"19","author":"X Wang","year":"2024","unstructured":"Wang, X., Bai, H., Zhang, J., Wang, Z., Duan, J., Cai, H., et al. (2024). Genetic intratumor heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer. Journal of Thoracic Oncology, 19(2), 252\u2013272.","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10380_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-020-0215-2","volume":"21","author":"A Baluapuri","year":"2020","unstructured":"Baluapuri, A., Wolf, E., & Eilers, M. (2020). Target gene-independent functions of MYC oncoproteins. Nature Reviews Molecular Cell Biology, 21(5), 255\u2013267.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"1","key":"10380_CR46","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli, D., Brambillasca, C. S., Talens, F., Bhin, J., Linstra, R., Romanens, L., et al. (2022). MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nature Communications, 13(1), 6579.","journal-title":"Nature Communications"},{"issue":"2","key":"10380_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101937","volume":"6","author":"S Arce-Gallego","year":"2025","unstructured":"Arce-Gallego, S., Cresta Morgado, P., Delgado-Serrano, L., Simonetti, S., Gonzalez, M., Romero-Lozano, P., et al. (2025). Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Reports Medicine, 6(2), Article 101937.","journal-title":"Cell Reports Medicine"},{"issue":"18","key":"10380_CR48","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","volume":"187","author":"Y Luo","year":"2024","unstructured":"Luo, Y., Xia, Y., Liu, D., Li, X., Li, H., Liu, J., et al. (2024). Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell, 187(18), 4905\u201325.e24.","journal-title":"Cell"},{"issue":"11","key":"10380_CR49","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.scib.2025.03.054","volume":"70","author":"K Ma","year":"2025","unstructured":"Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025). T cell-based cancer immunotherapy: Opportunities and challenges. Science Bulletin, 70(11), 1872\u20131890.","journal-title":"Science Bulletin"},{"issue":"7755","key":"10380_CR50","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang, W., Green, M., Choi, J. E., Gij\u00f3n, M., Kennedy, P. D., Johnson, J. K., et al. (2019). CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 569(7755), 270\u2013274.","journal-title":"Nature"},{"issue":"2","key":"10380_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., et al. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 171(2), 273\u2013285.","journal-title":"Cell"},{"issue":"1","key":"10380_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-023-02677-2","volume":"42","author":"A Saha","year":"2023","unstructured":"Saha, A., Zhao, S., Kindall, A., Wilder, C., Friedman, C. A., Clark, R., et al. (2023). Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition. Journal of Experimental & Clinical Cancer Research, 42(1), 119.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"3","key":"10380_CR53","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo, C., Figueiredo, I., Gurel, B., Neeb, A., Seed, G., Crespo, M., et al. (2023). B7-H3 as a therapeutic target in advanced prostate cancer. European Urology, 83(3), 224\u2013238.","journal-title":"European Urology"},{"issue":"7941","key":"10380_CR54","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I Vazquez-Garcia","year":"2022","unstructured":"Vazquez-Garcia, I., Uhlitz, F., Ceglia, N., Lim, J. L. P., Wu, M., Mohibullah, N., et al. (2022). Ovarian cancer mutational processes drive site-specific immune evasion. Nature, 612(7941), 778.","journal-title":"Nature"},{"issue":"2","key":"10380_CR55","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.32150","volume":"75","author":"F Carapeto","year":"2022","unstructured":"Carapeto, F., Bozorgui, B., Shroff, R. T., Chagani, S., Solis Soto, L., Foo, W. C., et al. (2022). The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology, 75(2), 297\u2013308.","journal-title":"Hepatology"},{"issue":"4","key":"10380_CR56","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41588-024-01688-9","volume":"56","author":"AD Reed","year":"2024","unstructured":"Reed, A. D., Pensa, S., Steif, A., Stenning, J., Kunz, D. J., Porter, L. J., et al. (2024). A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast. Nature Genetics, 56(4), 652\u2013662.","journal-title":"Nature Genetics"},{"issue":"4","key":"10380_CR57","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta, L., & Pollard, J. W. (2023). A timeline of tumour-associated macrophage biology. Nature Reviews Cancer, 23(4), 238\u2013257.","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10380_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hep.32335","volume":"77","author":"H Ma","year":"2023","unstructured":"Ma, H., Kang, Z., Foo, T. K., Shen, Z., & Xia, B. (2023). Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway. Hepatology, 77(1), 33\u201347.","journal-title":"Hepatology"},{"issue":"10","key":"10380_CR59","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/ncb1171","volume":"6","author":"WM ElShamy","year":"2004","unstructured":"ElShamy, W. M., & Livingston, D. M. (2004). Identification of BRCA1-IRIS, a BRCA1 locus product. Nature Cell Biology, 6(10), 954\u2013967.","journal-title":"Nature Cell Biology"},{"issue":"5","key":"10380_CR60","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/0008-5472.CAN-19-2374","volume":"80","author":"E Sami","year":"2020","unstructured":"Sami, E., Paul, B. T., Koziol, J. A., & ElShamy, W. M. (2020). The immunosuppressive microenvironment in BRCA1-IRIS-overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages. Cancer Research, 80(5), 1102\u20131117.","journal-title":"Cancer Research"},{"issue":"3","key":"10380_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.18632\/oncotarget.462","volume":"3","author":"Y Shimizu","year":"2012","unstructured":"Shimizu, Y., Mullins, N., Blanchard, Z., & Elshamy, W. M. (2012). BRCA1\/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. Oncotarget, 3(3), 299\u2013313.","journal-title":"Oncotarget"},{"issue":"1","key":"10380_CR62","first-page":"396","volume":"12","author":"P Castillo","year":"2022","unstructured":"Castillo, P., Aisagbonhi, O., Saenz, C. C., & ElShamy, W. M. (2022). Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: The case for longer breastfeeding. American Journal of Cancer Research, 12(1), 396\u2013426.","journal-title":"American Journal of Cancer Research"},{"issue":"14","key":"10380_CR63","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.7150\/ijbs.118427","volume":"21","author":"EJ Cho","year":"2025","unstructured":"Cho, E. J., Ki, M. K., Baek, H. J., Shin, D. H., Park, E. J., Kim, T. H., et al. (2025). Synergistic effects of radiotherapy and PD-1 blockade in a human-mimetic BRCAness model of triple-negative breast cancer. International Journal of Biological Sciences, 21(14), 6270\u20136284.","journal-title":"International Journal of Biological Sciences"},{"issue":"3","key":"10380_CR64","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","volume":"41","author":"L van Vlerken-Ysla","year":"2023","unstructured":"van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E., & Gabrilovich, D. I. (2023). Functional states of myeloid cells in cancer. Cancer Cell, 41(3), 490\u2013504.","journal-title":"Cancer Cell"},{"issue":"1","key":"10380_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29151-5","volume":"13","author":"J Li","year":"2022","unstructured":"Li, J., Shu, X., Xu, J., Su, S. M., Chan, U. I., Mo, L., et al. (2022). S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. Nature Communications, 13(1), Article 1481.","journal-title":"Nature Communications"},{"issue":"3","key":"10380_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq1395","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen, S., Shao, F., Zeng, J., Guo, S., Wang, L., Sun, H., et al. (2023). Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling. Science Advances, 9(3), Article eabq1395.","journal-title":"Science Advances"},{"issue":"5","key":"10380_CR67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai, S., Itahashi, K., & Nishikawa, H. (2024). Regulatory T cell-mediated immunosuppression orchestrated by cancer: Towards an immuno-genomic paradigm for precision medicine. Nature Reviews Clinical Oncology, 21(5), 337\u201353.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10380_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000228","author":"Q Zhou","year":"2020","unstructured":"Zhou, Q., Qi, Y., Wang, Z., Zeng, H., Zhang, H., Liu, Z., et al. (2020). CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer, 8(1), e000228.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"15","key":"10380_CR69","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1158\/0008-5472.CAN-22-3398","volume":"83","author":"X Shu","year":"2023","unstructured":"Shu, X., Li, J., Chan, U. I., Su, S. M., Shi, C., Zhang, X., et al. (2023). BRCA1 insufficiency induces a hypersialylated acidic tumor microenvironment that promotes metastasis and immunotherapy resistance. Cancer Research, 83(15), 2614\u20132633.","journal-title":"Cancer Research"},{"issue":"3","key":"10380_CR70","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri, G., & Tuveson, D. A. (2023). Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell, 41(3), 434\u2013449.","journal-title":"Cancer Cell"},{"issue":"8","key":"10380_CR71","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra, Y., & Weeraratna, A. T. (2023). Fibroblasts in cancer: Unity in heterogeneity. Cell, 186(8), 1580\u20131609.","journal-title":"Cell"},{"issue":"1","key":"10380_CR72","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi, G., & Tuveson, D. A. (2021). Diversity and biology of cancer-associated fibroblasts. Physiological Reviews, 101(1), 147\u2013176.","journal-title":"Physiological Reviews"},{"issue":"7","key":"10380_CR73","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s43018-020-0082-y","volume":"1","author":"G Friedman","year":"2020","unstructured":"Friedman, G., Levi-Galibov, O., David, E., Bornstein, C., Giladi, A., Dadiani, M., et al. (2020). Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome. Nature Cancer, 1(7), 692\u2013708.","journal-title":"Nature Cancer"},{"issue":"1","key":"10380_CR74","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1038\/s41467-022-34081-3","volume":"13","author":"L Shaashua","year":"2022","unstructured":"Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., et al. (2022). BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling. Nature Communications, 13(1), 6513.","journal-title":"Nature Communications"},{"issue":"851","key":"10380_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady2719","volume":"18","author":"D Liu","year":"2026","unstructured":"Liu, D., Tao, K., Cai, C., Lin, Y., Yu, R., Xiong, K., et al. (2026). Genomic instability drives POSTN(+) myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer. Science Translational Medicine, 18(851), Article eady2719.","journal-title":"Science Translational Medicine"},{"issue":"8","key":"10380_CR76","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","volume":"23","author":"Q Zeng","year":"2023","unstructured":"Zeng, Q., Mousa, M., Nadukkandy, A. S., Franssens, L., Alnaqbi, H., Alshamsi, F. Y., et al. (2023). Understanding tumour endothelial cell heterogeneity and function from single-cell omics. Nature Reviews. Cancer, 23(8), 544\u201364.","journal-title":"Nature Reviews. Cancer"},{"issue":"3","key":"10380_CR77","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41416-018-0157-z","volume":"119","author":"I Ruscito","year":"2018","unstructured":"Ruscito, I., Cacsire Castillo-Tong, D., Vergote, I., Ignat, I., Stanske, M., Vanderstichele, A., et al. (2018). Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: Clinico-pathological impact (an OCTIPS Consortium study). British Journal of Cancer, 119(3), 330\u20138.","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10380_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109412","volume":"36","author":"M Bruand","year":"2021","unstructured":"Bruand, M., Barras, D., Mina, M., Ghisoni, E., Morotti, M., Lanitis, E., et al. (2021). Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Reports, 36(3), Article 109412.","journal-title":"Cell Reports"},{"issue":"3","key":"10380_CR79","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10565-015-9303-z","volume":"31","author":"A Ptak","year":"2015","unstructured":"Ptak, A., & Gregoraszczuk, E. L. (2015). Effects of bisphenol A and 17\u03b2-estradiol on vascular endothelial growth factor A and its receptor expression in the non-cancer and cancer ovarian cell lines. Cell Biology and Toxicology, 31(3), 187\u2013197.","journal-title":"Cell Biology and Toxicology"},{"issue":"3","key":"10380_CR80","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1160\/TH08-12-0830","volume":"102","author":"B Schweighofer","year":"2009","unstructured":"Schweighofer, B., Testori, J., Sturtzel, C., Sattler, S., Mayer, H., Wagner, O., et al. (2009). The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thrombosis and Haemostasis, 102(3), 544\u2013554.","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10380_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trecan.2021.11.006","volume":"8","author":"V Klapp","year":"2022","unstructured":"Klapp, V., & Galluzzi, L. (2022). Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma. Trends in Cancer, 8(1), 1\u20133.","journal-title":"Trends in Cancer"},{"issue":"1","key":"10380_CR82","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","volume":"145","author":"A Ashworth","year":"2011","unstructured":"Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011). Genetic interactions in cancer progression and treatment. Cell, 145(1), 30\u201338.","journal-title":"Cell"},{"issue":"6082","key":"10380_CR83","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.1216338","volume":"336","author":"MF Langelier","year":"2012","unstructured":"Langelier, M. F., Planck, J. L., Roy, S., & Pascal, J. M. (2012). Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science, 336(6082), 728\u2013732.","journal-title":"Science"},{"issue":"6","key":"10380_CR84","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C., Sonzogni, O., De Oliveria, T. M., Mehta, A. K., Kothari, A., Wang, D., et al. (2019). PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discovery, 9(6), 722\u2013737.","journal-title":"Cancer Discovery"},{"issue":"11","key":"10380_CR85","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L., Kim, H. J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., et al. (2018). PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Reports, 25(11), 2972\u201380.e5.","journal-title":"Cell Reports"},{"issue":"1","key":"10380_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30568-1","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang, Q., Bergholz, J. S., Ding, L., Lin, Z., Kabraji, S. K., Hughes, M. E., et al. (2022). STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications, 13(1), Article 3022.","journal-title":"Nature Communications"},{"issue":"11","key":"10380_CR87","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","volume":"19","author":"SJ Hogg","year":"2020","unstructured":"Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020). Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 19(11), 776\u2013800.","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"10380_CR88","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc, R. S., & Richard, S. (2017). Arginine methylation: The coming of age. Molecular Cell, 65(1), 8\u201324.","journal-title":"Molecular Cell"},{"issue":"6","key":"10380_CR89","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/nar\/gkaa065","volume":"48","author":"F Liu","year":"2020","unstructured":"Liu, F., Xu, Y., Lu, X., Hamard, P. J., Karl, D. L., Man, N., et al. (2020). PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2. Nucleic Acids Research, 48(6), 2956\u201368.","journal-title":"Nucleic Acids Research"},{"key":"10380_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332998","author":"J Elurbide","year":"2024","unstructured":"Elurbide, J., Colyn, L., Latasa, M. U., Uriarte, I., Mariani, S., Lopez-Pascual, A., et al. (2024). Identification of PRMT5 as a therapeutic target in cholangiocarcinoma. Gut, 74(1), 116\u2013127.","journal-title":"Gut"},{"issue":"2","key":"10380_CR91","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","volume":"39","author":"P Kalev","year":"2021","unstructured":"Kalev, P., Hyer, M. L., Gross, S., Konteatis, Z., Chen, C. C., Fletcher, M., et al. (2021). MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell, 39(2), 209\u201324.e11.","journal-title":"Cancer Cell"},{"issue":"6","key":"10380_CR92","volume":"13","author":"Z Zhang","year":"2026","unstructured":"Zhang, Z., Zhang, S., Guo, L., Pan, Y., Huang, J., Ji, Y., et al. (2026). Interferon-driven biomarkers and synergistic therapy for PRMT5 inhibition in triple-negative breast cancer. Advanced Science (Weinheim), 13(6), Article e05787.","journal-title":"Advanced Science (Weinheim)"},{"issue":"12","key":"10380_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101326","volume":"4","author":"Y Li","year":"2023","unstructured":"Li, Y., Dobrolecki, L. E., Sallas, C., Zhang, X., Kerr, T. D., Bisht, D., et al. (2023). PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Reports Medicine, 4(12), Article 101326.","journal-title":"Cell Reports Medicine"},{"issue":"5","key":"10380_CR94","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi, H., Hsu, J. M., Yang, W. H., & Hung, M. C. (2022). Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nature Reviews Clinical Oncology, 19(5), 287\u2013305.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"6","key":"10380_CR95","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","volume":"74","author":"X Tu","year":"2019","unstructured":"Tu, X., Qin, B., Zhang, Y., Zhang, C., Kahila, M., Nowsheen, S., et al. (2019). PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Molecular Cell, 74(6), 1215\u201326.e4.","journal-title":"Molecular Cell"},{"issue":"11","key":"10380_CR96","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1158\/0008-5472.CAN-21-2076","volume":"82","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati, A. V. R., Boyd, J. T., Murray, C. E., Saifetiarova, J., de la Pe\u00f1a Avalos, B., Rogers, C. M., et al. (2022). Tumor intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality. Cancer Research, 82(11), 2156\u201370.","journal-title":"Cancer Research"},{"issue":"7813","key":"10380_CR97","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","volume":"582","author":"PL Sulkowski","year":"2020","unstructured":"Sulkowski, P. L., Oeck, S., Dow, J., Economos, N. G., Mirfakhraie, L., Liu, Y., et al. (2020). Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature, 582(7813), 586\u2013591.","journal-title":"Nature"},{"issue":"4","key":"10380_CR98","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41581-023-00800-2","volume":"20","author":"NJ Coffey","year":"2024","unstructured":"Coffey, N. J., & Simon, M. C. (2024). Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature Reviews. Nephrology, 20(4), 233\u2013250.","journal-title":"Nature Reviews. Nephrology"},{"issue":"728","key":"10380_CR99","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7740","volume":"16","author":"JH Ding","year":"2024","unstructured":"Ding, J. H., Xiao, Y., Yang, F., Song, X. Q., Xu, Y., Ding, X. H., et al. (2024). Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer. Science Translational Medicine, 16(728), Article eadg7740.","journal-title":"Science Translational Medicine"},{"issue":"16","key":"10380_CR100","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., et al. (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. New England Journal of Medicine, 363(16), 1532\u20131543.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10380_CR101","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccell.2023.03.002","volume":"41","author":"W Zhou","year":"2023","unstructured":"Zhou, W., Liu, H., Yuan, Z., Zundell, J., Towers, M., Lin, J., et al. (2023). Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell, 41(4), 740\u201356.e10.","journal-title":"Cancer Cell"},{"issue":"10","key":"10380_CR102","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1093\/nar\/gkae233","volume":"52","author":"A Bakr","year":"2024","unstructured":"Bakr, A., Corte, G. D., Veselinov, O., Kelek\u00e7i, S., Chen, M. M., Lin, Y. Y., et al. (2024). ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic Acids Research, 52(10), 5698\u20135719.","journal-title":"Nucleic Acids Research"},{"issue":"3","key":"10380_CR103","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ccell.2020.05.022","volume":"38","author":"H Yuan","year":"2020","unstructured":"Yuan, H., Han, Y., Wang, X., Li, N., Liu, Q., Yin, Y., et al. (2020). SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways. Cancer Cell, 38(3), 350\u201365.e7.","journal-title":"Cancer Cell"},{"issue":"4","key":"10380_CR104","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/gutjnl-2019-318362","volume":"69","author":"N Niu","year":"2020","unstructured":"Niu, N., Lu, P., Yang, Y., He, R., Zhang, L., Shi, J., et al. (2020). Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis. Gut, 69(4), 715\u2013726.","journal-title":"Gut"},{"issue":"6","key":"10380_CR105","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.celrep.2014.05.026","volume":"7","author":"SX Pfister","year":"2014","unstructured":"Pfister, S. X., Ahrabi, S., Zalmas, L. P., Sarkar, S., Aymard, F., Bachrati, C. Z., et al. (2014). SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Reports, 7(6), 2006\u201318.","journal-title":"Cell Reports"},{"issue":"6","key":"10380_CR106","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11427-024-2543-9","volume":"67","author":"R Chen","year":"2024","unstructured":"Chen, R., Zhao, M. J., Li, Y. M., Liu, A. H., Wang, R. X., Mei, Y. C., et al. (2024). Di- and tri-methylation of histone H3K36 play distinct roles in DNA double-strand break repair. Science China. Life Sciences, 67(6), 1089\u20131105.","journal-title":"Science China. Life Sciences"},{"issue":"22","key":"10380_CR107","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1158\/0008-5472.CAN-23-0401","volume":"83","author":"X Zhou","year":"2023","unstructured":"Zhou, X., Sekino, Y., Li, H. T., Fu, G., Yang, Z., Zhao, S., et al. (2023). SETD2 deficiency confers sensitivity to dual inhibition of DNA methylation and PARP in kidney cancer. Cancer Research, 83(22), 3813\u20133826.","journal-title":"Cancer Research"},{"issue":"7688","key":"10380_CR108","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature25170","volume":"553","author":"G Sulli","year":"2018","unstructured":"Sulli, G., Rommel, A., Wang, X., Kolar, M. J., Puca, F., Saghatelian, A., et al. (2018). Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature, 553(7688), 351\u2013355.","journal-title":"Nature"},{"issue":"9","key":"10380_CR109","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1158\/0008-5472.CAN-16-2099","volume":"77","author":"NL Ka","year":"2017","unstructured":"Ka, N. L., Na, T. Y., Na, H., Lee, M. H., Park, H. S., Hwang, S., et al. (2017). NR1D1 recruitment to sites of DNA damage inhibits repair and is associated with chemosensitivity of breast cancer. Cancer Research, 77(9), 2453\u20132463.","journal-title":"Cancer Research"},{"issue":"18","key":"10380_CR110","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1158\/0008-5472.CAN-23-0329","volume":"83","author":"NL Ka","year":"2023","unstructured":"Ka, N. L., Park, M. K., Kim, S. S., Jeon, Y., Hwang, S., Kim, S. M., et al. (2023). NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling. Cancer Research, 83(18), 3045\u20133058.","journal-title":"Cancer Research"},{"issue":"18","key":"10380_CR111","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1016\/j.cell.2023.07.013","volume":"186","author":"Y Geffen","year":"2023","unstructured":"Geffen, Y., Anand, S., Akiyama, Y., Yaron, T. M., Song, Y., Johnson, J. L., et al. (2023). Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell, 186(18), 3945\u201367.e26.","journal-title":"Cell"},{"key":"10380_CR112","doi-asserted-by":"crossref","unstructured":"Oh, G., Wang, A., Wang, L., Li, J., Werba, G., Weissinger, D., et al. (2023). POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS\/STING signaling. Journal of Clinical Investigation, 133(11), e165934.","DOI":"10.1172\/JCI165934"},{"issue":"6","key":"10380_CR113","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","volume":"2","author":"J Zhou","year":"2021","unstructured":"Zhou, J., Gelot, C., Pantelidou, C., Li, A., Y\u00fccel, H., Davis, R. E., et al. (2021). A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. Nature Cancer, 2(6), 598\u2013610.","journal-title":"Nature Cancer"},{"issue":"14","key":"10380_CR114","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-22-3394","volume":"29","author":"J Hwang","year":"2023","unstructured":"Hwang, J., Shi, X., Elliott, A., Arnoff, T. E., McGrath, J., Xiu, J., et al. (2023). Metastatic prostate cancers with BRCA2 versus ATM mutations exhibit divergent molecular features and clinical outcomes. Clinical Cancer Research, 29(14), 2702\u20132713.","journal-title":"Clinical Cancer Research"},{"issue":"22","key":"10380_CR115","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1101\/gad.288282.116","volume":"30","author":"R V\u00e9lez-Cruz","year":"2016","unstructured":"V\u00e9lez-Cruz, R., Manickavinayaham, S., Biswas, A. K., Clary, R. W., Premkumar, T., Cole, F., et al. (2016). RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1. Genes & Development, 30(22), 2500\u20132512.","journal-title":"Genes & Development"},{"issue":"7553","key":"10380_CR116","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch, A. M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., et al. (2015). Whole-genome characterization of chemoresistant ovarian cancer. Nature, 521(7553), 489\u2013494.","journal-title":"Nature"},{"issue":"7418","key":"10380_CR117","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular portraits of human breast tumours","year":"2012","unstructured":"Comprehensive molecular portraits of human breast tumours. (2012). Nature, 490(7418), 61\u201370.","journal-title":"Nature"},{"issue":"7","key":"10380_CR118","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-21-2096","volume":"28","author":"CB Westphalen","year":"2022","unstructured":"Westphalen, C. B., Fine, A. D., Andr\u00e9, F., Ganesan, S., Heinemann, V., Rouleau, E., et al. (2022). Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-heterozygosity score. Clinical Cancer Research, 28(7), 1412\u20131421.","journal-title":"Clinical Cancer Research"},{"issue":"16","key":"10380_CR119","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1158\/1078-0432.CCR-23-3552","volume":"30","author":"FAM Saner","year":"2024","unstructured":"Saner, F. A. M., Takahashi, K., Budden, T., Pandey, A., Ariyaratne, D., Zwimpfer, T. A., et al. (2024). Concurrent RB1 loss and BRCA deficiency predicts enhanced immunologic response and long-term survival in tubo-ovarian high-grade serous carcinoma. Clinical Cancer Research, 30(16), 3481\u20133498.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10380_CR120","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4161\/epi.6.5.15667","volume":"6","author":"OA Stefansson","year":"2011","unstructured":"Stefansson, O. A., Jonasson, J. G., Olafsdottir, K., Hilmarsdottir, H., Olafsdottir, G., Esteller, M., et al. (2011). CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer. Epigenetics, 6(5), 638\u2013649.","journal-title":"Epigenetics"},{"issue":"11","key":"10380_CR121","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/annonc\/mdp209","volume":"20","author":"D Trer\u00e9","year":"2009","unstructured":"Trer\u00e9, D., Brighenti, E., Donati, G., Ceccarelli, C., Santini, D., Taffurelli, M., et al. (2009). High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Annals of Oncology, 20(11), 1818\u20131823.","journal-title":"Annals of Oncology"},{"key":"10380_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-026-00570-3","author":"F Blanc-Durand","year":"2026","unstructured":"Blanc-Durand, F., Yaniz Galende, E., Ferron, G., Kaminsky, M. C., Kalbacher, E., Abadie-Lacourtoisie, S., et al. (2026). Immuno-molecular features associated with exceptional recurrence-free survivorship from ovarian cancer in the pre-PARP era. NPJ Genomic Medicine, 11(1), 37.","journal-title":"NPJ Genomic Medicine"},{"issue":"7909","key":"10380_CR123","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41586-022-04698-x","volume":"605","author":"JM Suski","year":"2022","unstructured":"Suski, J. M., Ratnayeke, N., Braun, M., Zhang, T., Strmiska, V., Michowski, W., et al. (2022). CDC7-independent G1\/S transition revealed by targeted protein degradation. Nature, 605(7909), 357\u201365.","journal-title":"Nature"},{"key":"10380_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403782","author":"S Liu","year":"2024","unstructured":"Liu, S., Deng, P., Yu, Z., Hong, J. H., Gao, J., Huang, Y., et al. (2024). CDC7 inhibition potentiates antitumor efficacy of PARP inhibitor in advanced ovarian cancer. Advanced Science, 11(45), e2403782.","journal-title":"Advanced Science"},{"issue":"6","key":"10380_CR125","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","volume":"82","author":"Z Wilson","year":"2022","unstructured":"Wilson, Z., Odedra, R., Wallez, Y., Wijnhoven, P. W. G., Hughes, A. M., Gerrard, J., et al. (2022). ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Research, 82(6), 1140\u20131152.","journal-title":"Cancer Research"},{"key":"10380_CR126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","author":"MT Dillon","year":"2024","unstructured":"Dillon, M. T., Guevara, J., Mohammed, K., Patin, E. C., Smith, S. A., Dean, E., et al. (2024). Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. Journal of Clinical Investigation, 134(2), e175369.","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10380_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00959-2","volume":"13","author":"A GhelliLuserna di Ror\u00e0","year":"2020","unstructured":"GhelliLuserna di Ror\u00e0, A., Cerchione, C., Martinelli, G., & Simonetti, G. (2020). A WEE1 family business: Regulation of mitosis, cancer progression, and therapeutic target. Journal of Hematology & Oncology, 13(1), Article 126.","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10380_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00568-5","volume":"9","author":"ZL Teo","year":"2023","unstructured":"Teo, Z. L., O\u2019Connor, M. J., Versaci, S., Clarke, K. A., Brown, E. R., Percy, L. W., et al. (2023). Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1\/2 wildtype triple-negative breast cancer. NPJ Breast Cancer, 9(1), Article 68.","journal-title":"NPJ Breast Cancer"},{"key":"10380_CR129","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R., & Engleman, E. G. (2021). Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223\u2013249.","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"issue":"7","key":"10380_CR130","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., et al. (2024). Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nature Reviews Cancer, 24(7), 498\u2013512.","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10380_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01283-7","volume":"15","author":"Z Zhou","year":"2022","unstructured":"Zhou, Z., Ding, Z., Yuan, J., Shen, S., Jian, H., Tan, Q., et al. (2022). Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients. Journal of Hematology & Oncology, 15(1), Article 62.","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10380_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58440-y","volume":"16","author":"SL Aronson","year":"2025","unstructured":"Aronson, S. L., Thijssen, B., Lopez-Yurda, M., Koole, S. N., van der Leest, P., Le\u00f3n-Castillo, A., et al. (2025). Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: The phase II Neo-Pembro trial. Nature Communications, 16(1), Article 3520.","journal-title":"Nature Communications"},{"issue":"17","key":"10380_CR133","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., et al. (2018). Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. Journal of Clinical Oncology, 36(17), 1685\u20131694.","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10380_CR134","first-page":"346","volume":"15","author":"D Romero","year":"2018","unstructured":"Romero, D. (2018). DDR signature to predict response to ICI. Nature Reviews Clinical Oncology, 15(6), 346.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"6","key":"10380_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0611","volume":"8","author":"G Terrero","year":"2022","unstructured":"Terrero, G., Datta, J., Dennison, J., Sussman, D. A., Lohse, I., Merchant, N. B., et al. (2022). Ipilimumab\/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncology, 8(6), 1\u20133.","journal-title":"JAMA Oncology"},{"issue":"12","key":"10380_CR136","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","volume":"35","author":"S van Wilpe","year":"2024","unstructured":"van Wilpe, S., Kloots, I. S. H., Slootbeek, P. H. J., den Brok, M., Westdorp, H., Franken, M. D., et al. (2024). Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: Primary analysis of the phase II INSPIRE trial. Annals of Oncology, 35(12), 1126\u20131137.","journal-title":"Annals of Oncology"},{"issue":"2","key":"10380_CR137","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1158\/2159-8290.CD-20-0818","volume":"11","author":"S Iyer","year":"2021","unstructured":"Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., et al. (2021). Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. Cancer Discovery, 11(2), 384\u2013407.","journal-title":"Cancer Discovery"},{"issue":"9","key":"10380_CR138","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-22-2032","volume":"29","author":"CN Landen","year":"2023","unstructured":"Landen, C. N., Molinero, L., Hamidi, H., Sehouli, J., Miller, A., Moore, K. N., et al. (2023). Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: Biomarker analyses from the IMagyn050 randomized clinical trial. Clinical Cancer Research, 29(9), 1698\u20131707.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10380_CR139","doi-asserted-by":"publisher","first-page":"e217728","DOI":"10.1001\/jamanetworkopen.2021.7728","volume":"4","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z., & Li, M. (2021). Evaluation of BRCA1 and BRCA2 as indicators of response to immune checkpoint inhibitors. JAMA Network Open, 4(5), e217728.","journal-title":"JAMA Network Open"},{"issue":"15","key":"10380_CR140","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.7150\/thno.59056","volume":"11","author":"Z Shi","year":"2021","unstructured":"Shi, Z., Shen, J., Qiu, J., Zhao, Q., Hua, K., & Wang, H. (2021). CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors. Theranostics, 11(15), 7175\u20137187.","journal-title":"Theranostics"},{"issue":"2","key":"10380_CR141","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B., McQuinn, C. W., Loftus, S., et al. (2018). IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut, 67(2), 320\u2013332.","journal-title":"Gut"},{"issue":"1","key":"10380_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11048-5","volume":"10","author":"T Reisl\u00e4nder","year":"2019","unstructured":"Reisl\u00e4nder, T., Lombardi, E. P., Groelly, F. J., Miar, A., Porru, M., Di Vito, S., et al. (2019). BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nature Communications, 10(1), Article 3143.","journal-title":"Nature Communications"},{"issue":"2","key":"10380_CR143","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen, J., Zhao, W., Ju, Z., Wang, L., Peng, Y., Labrie, M., et al. (2019). PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Research, 79(2), 311\u2013319.","journal-title":"Cancer Research"},{"issue":"17","key":"10380_CR144","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1158\/1078-0432.CCR-21-1278","volume":"28","author":"T Kumar","year":"2022","unstructured":"Kumar, T., Hobbs, E., Yang, F., Chang, J. T., Contreras, A., Cuentas, E. R. P., et al. (2022). Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation. Clinical Cancer Research, 28(17), 3669\u20133676.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10380_CR145","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","volume":"9","author":"AM Schram","year":"2023","unstructured":"Schram, A. M., Colombo, N., Arrowsmith, E., Narayan, V., Yonemori, K., Scambia, G., et al. (2023). Avelumab plus talazoparib in patients with BRCA1\/2- or ATM-altered advanced solid tumors: Results from JAVELIN BRCA\/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial. JAMA Oncology, 9(1), 29\u201339.","journal-title":"JAMA Oncology"},{"issue":"9","key":"10380_CR146","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek, S. M., Postel-Vinay, S., Im, S. A., Park, Y. H., Delord, J. P., Italiano, A., et al. (2020). Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1\/2, basket study. Lancet Oncology, 21(9), 1155\u20131164.","journal-title":"Lancet Oncology"},{"key":"10380_CR147","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004761","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K., Retz, M., Petrylak, D. P., Goh, J. C., Perez-Gracia, J., Lacombe, L., et al. (2022). Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial. Journal for ImmunoTherapy of Cancer, 10(8), e004761.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"12","key":"10380_CR148","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1158\/1078-0432.CCR-25-4467","volume":"32","author":"MM Rubinstein","year":"2026","unstructured":"Rubinstein, M. M., Ge, J. Y., Zhou, Q., Iasonos, A., Weigelt, B., Selenica, P., et al. (2026). A phase II trial of olaparib plus pembrolizumab in patients with recurrent copy number-high\/p53-abnormal endometrial cancer. Clinical Cancer Research, 32(12), 2362\u20132371.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10380_CR149","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41591-026-04299-5","volume":"32","author":"W Park","year":"2026","unstructured":"Park, W., O\u2019Connor, C. A., Chou, J. F., Hilmi, M., Tarcan, Z., Schwartz, C., et al. (2026). Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: The phase 2 POLAR trial. Nature Medicine, 32(5), 1783\u20131793.","journal-title":"Nature Medicine"},{"issue":"5","key":"10380_CR150","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","volume":"30","author":"F Passiglia","year":"2024","unstructured":"Passiglia, F., Righi, L., Bironzo, P., List\u00ec, A., Farinea, G., Capelletto, E., et al. (2024). Niraparib plus dostarlimab in pleural mesothelioma or non-small cell lung cancer harboring HRR mutations: Interim results of the UNITO-001 phase II prospective trial. Clinical Cancer Research, 30(5), 959\u2013964.","journal-title":"Clinical Cancer Research"},{"issue":"36","key":"10380_CR151","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.24.00668","volume":"42","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2024","unstructured":"Gonz\u00e1lez-Mart\u00edn, A., Rubio, M. J., Heitz, F., Depont Christensen, R., Colombo, N., Van Gorp, T., et al. (2024). Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval > 6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III trial. Journal of Clinical Oncology., 42(36), 4294\u20134304.","journal-title":"Journal of Clinical Oncology."},{"issue":"12","key":"10380_CR152","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.annonc.2025.05.009","volume":"36","author":"AC Hardy-Bessard","year":"2025","unstructured":"Hardy-Bessard, A. C., Pujade-Lauraine, E., Moore, R. G., Montestruc, F., Redondo, A., Mirza, M. R., et al. (2025). Dostarlimab and niraparib in primary advanced ovarian cancer. Annals of Oncology, 36(12), 1503\u20131513.","journal-title":"Annals of Oncology"},{"key":"10380_CR153","doi-asserted-by":"publisher","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J., Oaknin, A., O\u2019Malley, D. M., Wilson, M., Lorusso, D., Westin, S., et al. (2024). LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). Annals of Oncology., 35, S1223\u2013S1224.","journal-title":"Annals of Oncology."},{"issue":"4","key":"10380_CR154","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","volume":"37","author":"P Harter","year":"2026","unstructured":"Harter, P., Trillsch, F., Okamoto, A., Reuss, A., Kim, J. W., Rubio-P\u00e9rez, M. J., et al. (2026). Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Annals of Oncology, 37(4), 503\u2013520.","journal-title":"Annals of Oncology"},{"issue":"8","key":"10380_CR155","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., Gonz\u00e1lez-Mart\u00edn, A., Marth, C., et al. (2023). Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Annals of Oncology, 34(8), 681\u2013692.","journal-title":"Annals of Oncology"},{"issue":"25","key":"10380_CR156","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I., Pautier, P., Pignata, S., P\u00e9rol, D., Gonz\u00e1lez-Mart\u00edn, A., Berger, R., et al. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine, 381(25), 2416\u20132428.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10380_CR157","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2021","unstructured":"Mehta, A. K., Cheney, E. M., Hartl, C. A., Pantelidou, C., Oliwa, M., Castrillon, J. A., et al. (2021). Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature Cancer, 2(1), 66\u201382.","journal-title":"Nature Cancer"},{"issue":"6","key":"10380_CR158","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., et al. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell, 25(6), 846\u2013859.","journal-title":"Cancer Cell"},{"issue":"1","key":"10380_CR159","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41698-021-00189-w","volume":"5","author":"X Li","year":"2021","unstructured":"Li, X., Fang, T., Xu, S., Jin, P., Zhou, D., Wang, Z., et al. (2021). PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer. NPJ Precis Oncol., 5(1), 49.","journal-title":"NPJ Precis Oncol."},{"issue":"4","key":"10380_CR160","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/1535-7163.MCT-22-0396","volume":"22","author":"P Jin","year":"2023","unstructured":"Jin, P., Li, X., Xia, Y., Li, H., Li, X., Yang, Z. Y., et al. (2023). Bepotastine sensitizes ovarian cancer to PARP inhibitors through suppressing NF-\u03baB-triggered SASP in cancer-associated fibroblasts. Molecular Cancer Therapeutics, 22(4), 447\u2013458.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"6","key":"10380_CR161","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","volume":"160","author":"T Golan","year":"2021","unstructured":"Golan, T., O\u2019Kane, G. M., Denroche, R. E., Raitses-Gurevich, M., Grant, R. C., Holter, S., et al. (2021). Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology, 160(6), 2119\u201332.e9.","journal-title":"Gastroenterology"},{"issue":"10","key":"10380_CR162","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-024-03782-7","volume":"73","author":"C Park","year":"2024","unstructured":"Park, C., Suh, K. J., Kim, S. H., Lee, K. H., Im, S. A., Kim, M. H., et al. (2024). Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer. Cancer Immunol Immunother, 73(10), 197.","journal-title":"Cancer Immunol Immunother"},{"key":"10380_CR163","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12885-023-11260-z","volume":"23","author":"S O'Brien","year":"2023","unstructured":"O\u2019Brien, S., Butticello, M., Thompson, C., Wilson, B., Wyce, A., Mahajan, V., et al. (2023). Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. BMC Cancer, 23, 775.","journal-title":"BMC Cancer"},{"issue":"1","key":"10380_CR164","doi-asserted-by":"publisher","first-page":"36766","DOI":"10.1038\/s41598-025-20696-1","volume":"15","author":"S Suresh","year":"2025","unstructured":"Suresh, S., McPherson, L., & Ford, J. M. (2025). PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1\/2 and MTAP status in breast cancer cells. Scientific Reports, 15, 36766.","journal-title":"Scientific Reports"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10380-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:03:19Z","timestamp":1790157799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10380-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":164,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10380"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10380-9","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm their consent to publish the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}